Trial · NCT07120776
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
NCT07120776, Not applicable, Recruiting, University of Manchester
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial. Trials, record NCT07120776. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07120776
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
- NCT number
- NCT07120776
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 75 participants, estimated
- Lead sponsor
- University of Manchester
- Conditions
- Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction, Myocardial Ischaemia
- Interventions
- Camzyos (Mavacamten)
- First posted
- 2025-08-13
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Myocardial Ischaemia: | 12 months | This will be assessed using Rubidium PET-CT. Looking at change in parameters such as global myocardial blood flow reserve (GMBFR) |
| Primary | Change in Myocardial Ischaemia: | 12 months | This will be assessed using Rubidium PET-CT. Looking at change in parameters such as global myocardial stress flow (GMSF). |
| Primary | Change in Myocardial Ischaemia: | 12 months | This will be assessed using Rubidium PET-CT. Looking at change in parameters such as coronary flow capacity (CFC). |
| Secondary | Patient-Reported Symptoms | 12 months | Secondary outcomes: 1\. Patient-Reported Symptoms: • Angina and Shortness of Breath: Changes in the frequency and severity of angina episodes and shortness of breath will be documented using validated the Seattle Angina Questionnaire- 7 (SAQ). Seattle Angina Questionnaire-7 (SAQ-7, 2014 version): The SAQ-7 is a validated, patient-reported outcome measure assessing the impact of angina on health status. It consists of 7 items covering 3 domains: Physical Limitation, Angina Frequency, and Quality of Life. Each domain is scored on a 0-100 scale, where higher scores indicate better health status (less angina, fewer physical limitations, and improved quality of life). Scores are transformed according to published scoring algorithms. The SAQ-7 Summary Score is the mean of the 3 domain scores. Minimum score: 0 (worst possible angina-related health status) Maximum score: 100 (no angina, no limitation, best possible quality of life) |
| Secondary | Patient-Reported Symptoms | 12 months | Secondary outcomes: 1\. Patient-Reported Symptoms: * Angina and Shortness of Breath: Changes in the frequency and severity of angina episodes and shortness of breath will be documented using validated the the HCM Shortness of Breath Questionnaire (HCMSQ-SoB) (also used in the EXPLORER-HCM trial) * The HCMSQ total score is as the equally weighted sum of the three domain scores, i.e., the sum of the SoB domain score divided by four (items), the tiredness domain score (a single item), and the CV symptom domain score divided by three (items), if all three domain scores are calculated; otherwise, the HCMSQ total score is missing. The potential range of scores is 0-12.5, with lower scores indicating a lower presence of symptoms overall/better health. |
| Secondary | Patient-Reported Symptoms | 12 months | Secondary outcomes: NYHA Functional Class: Improvement in NYHA functional class will be evaluated to assess changes in functional capacity and symptom severity. New York Heart Association (NYHA) Functional Classification - Ordinal scale ranging from Class I (no symptoms and no limitation in ordinary physical activity) to Class IV (severe limitations; symptoms present even at rest). Lower classes indicate better functional status, and improvement is reflected by a decrease in NYHA class from baseline. |
| Secondary | Subgroup Analyses | 12 months | Differences in Efficacy Based on Patient Subgroups: • Subgroup Analyses: The study will investigate differences in the impact of Mavacamten on myocardial ischemia and symptoms based on: o Age years (younger vs. older patients) |
| Secondary | Subgroup Analyses | 12 months | Differences in Efficacy Based on Patient Subgroups: • Subgroup Analyses: The study will investigate differences in the impact of Mavacamten on myocardial ischemia and symptoms based on: o Sex (male vs. female) |
| Secondary | Subgroup Analyses | 12 months | Differences in Efficacy Based on Patient Subgroups: • Subgroup Analyses: The study will investigate differences in the impact of Mavacamten on myocardial ischemia and symptoms based on: o Genetic Status (gene-positive vs. gene-negative vs VUS) |
| Secondary | Subgroup Analyses | 12 months | Differences in Efficacy Based on Patient Subgroups: • Subgroup Analyses: The study will investigate differences in the impact of Mavacamten on myocardial ischemia and symptoms based on: o Baseline LVOT Gradient Levels (mmHg) (higher vs. lower LVOT gradients) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32871100 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07120776
GET https://conductscience.org/api/trials/v1/NCT07120776/registered